|
NeuroSearch has dosed the first healthy volunteers in a clinical Phase I study with NSD-788 with a view to developing this drug candidate as a new treatment for anxiety and depression
BALLERUP, Denmark | March 31, 2008 | NeuroSearch has dosed the first healthy volunteers in a clinical Phase I study with NSD-788 with a view to developing this drug candidate as a new treatment for anxiety and depression. The Phase I study is a randomised, double-blind and placebo-controlled single ascending dose study to evaluate the compound’s safety, tolerability and pharmacokinetic profile after oral administration. The study is being performed in France.
Flemming Pedersen, CEO of NeuroSearch, comments:
“With the initiation of this Phase I study with NSD-788, NeuroSearch has now initiated three clinical programmes with new drug candidates within the past six months. This is a pleasant proof of the high productivity in our research laboratories which constantly deliver new candidates and thereby contribute to ensuring a continuous value growth in our development pipeline.”
NSD-788 is a new development candidate from the monoamine neurotransmitters drug discovery programme where NeuroSearch has built very broadly founded competences. NSD-788 has a unique effect on the monoamine re-uptake systems in the brain with primary effect on serotonin and dopamine. Based on studies in preclinical models, NeuroSearch believes that NSD-788 may show significant advantages over existing drugs for the treatment of anxiety, but also of other CNS disorders. NeuroSearch is performing the first phases of the clinical development of NSD-788 with a view to studying the compound’s anxiolytic properties and with special focus on certain specialist CNS indications.
The initiation of the Phase I study with NSD-788 does not change NeuroSearch’s expectations of a loss before financials in 2008 in the region of DKK 450 million, not including any kind of success-based payments that may be realised during the year, neither from existing nor from new partnership agreements.
SOURCE: NeuroSearch |
